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burden was 48.2%, 45.3% and 39.2%. CONCLUSIONS: The study suggests the 
economic burden of osteoporosis fractures is substantial in terms of LOS and 
inpatient costs and elderly fracture patients consume significantly more 
resources. Patient co-pay rates decreased due to an increase in the 
reimbursement rates from health care. The rising trend in osteoporosis fractures 
may pose a huge burden to China.  
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OBJECTIVES: Rheumatoid arthritis (RA), an autoimmune condition, and 
osteoarthritis (OA), a degenerative joint disorder, are both associated with 
inflammatory reactions. Pain relievers could ameliorate this economic burden; 
however depending on the first-line treatment chosen they could raise the 
likelihood of gastrointestinal (GI) complications or cardiovascular (CV) events. 
The aim of this study is to calculate the direct and indirect costs of GI and CV 
events associated with common pain relievers for RA and OA patients in Brazil, 
Mexico, Colombia, Argentina and Costa Rica from the public payer’s perspective. 
METHODS: Resource use and medical cost data was collected in 2011 from local 
official databases and public hospital records from each noted LA market (all 
costs are expressed in 2012 US$). Events considered in this assessment were: 
dyspepsia, symptomatic ulcer, major bleedings (severe GI complication), 
myocardial infarction, ischemic stroke and heart failure. Direct medical costs 
considered were: outpatient visits, inpatient costs, lab and diagnostic tests, 
acquisition drug costs, concomitant medication, and emergency room services. 
To estimate indirect costs, human capital approach was considered involving 
productivity losses based in average wages for each LA market. RESULTS: Among 
LA countries, Brazil showed the highest overall adverse event cost per patient 
with dyspepsia (US$97.10) and Costa Rica the lowest (US$57.00). In addition, a 
symptomatic ulcer cost ranged between US$933.00 - US$705.60; major bleeding 
(US$6,807.30 - US$4,960.40); myocardial infarction (US$13,330.30 - US$7916.70); 
ischemic stroke (US$6,427.20 - US$3125.00) and heart failure (US$7,221.70 - 
US$4,152.80). In average, Brazilian and Mexican overall costs were among the 
highest, as opposed to Argentina and Costa Rica which were among the 
countries with lowest costs. Indirect costs followed the same trend (less than 
15% of total direct costs). CONCLUSIONS: Unexpected event costs associated 
with pain relievers could raise the economic burden of OA and RA significantly 
in LA. Thus, these findings could help decision makers to identify cost-effective 
pain therapies in markets where this cost data is unavailable.  
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OBJECTIVES: Osteoarthritis (OA) and rheumatoid arthritis (RA) are conditions 
that are associated with significant clinical burden and impact patients’ 
functional status and quality of life. Medical costs related to treating these 
common and disabling conditions place an economic strain on health care 
systems. The aim of this assessment is to compare celecoxib against 
nonselective nonsteroidal anti-inflammatory drugs (nsNSAIDs) plus proton 
pump inhibitors (PPI) in five Latin American markets from the public payer’s 
perspective. METHODS: A cost-effectiveness evaluation was performed using a 
Markov modeling approach within a five-year time horizon (twelve-week cycles). 
The model compares celecoxib (200mg bid) against nsNSAIDs (naproxen 
500mg/bid; diclofenac 100mg/bid) alone and combined with PPI (omeprazole 
20mg/day). Model results were subdivided into two risk subpopulations: a) 
patients at low risk of GI and CV events (age 55+ with no prior risk factors); b) 
patients at high risk (age 65+ with previous risk factors). Efficacy and safety were 
retrieved from clinical literature (CONDOR Trial) and model uses Quality-
Adjusted Life Years Gained (QALYs) as effectiveness measurement. Resource use 
and medical cost data was collected from local official databases and public 
hospital records from each LA market (expressed in 2012 US$). Costs and 
consequences were discounted at 5% annually and probabilistic sensitivity 
analyses (PSA) were conducted. RESULTS: Celecoxib showed the highest health 
benefits (4.488 QALYs) compared to diclofenac (4.308 QALYs, +PPI 4.392 QALYs) 
and naproxen (4.241 QALYs, +PPI 4.355 QALYs). Regarding medical costs, in Brazil 
and Mexico celecoxib showed to be a cost-saving strategy within the high risk 
subpopulation. In other LA markets, celecoxib resulted as a cost-effective option 
with an average ICER of US$11,239.50 and US$8,046.20 in low and high risk 
subpopulations, respectively. PSA support robustness of the results. 
CONCLUSIONS: Despite higher acquisition cost compared to nsNSAIDs, celecoxib 
was found to be a cost-effective therapy for patients with OA and RA in multiple 
LA health care systems.  
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OBJECTIVES: Osteoporotic Fractures (OF) in elderly people are common 
worldwide, and the predicted aging of populations is increasing the burden of OF 
on health care systems. This study estimates the economic burden of OF in aged 
65 years and over in South Korea from a societal perspective. METHODS: 
National health insurance claim databases were used to analyze annual health 
care utilization and medical costs of OF in the South Korean population (49.78 
million). We identified medical claims records for elderly people with a diagnosis 
of OF and estimated the costs by a macro-costing method from 2007 to 2011. 
RESULTS: From 2007 to 2011, there were 244,798 elderly patients with at least 1 
medical insurance claim related to OF. Most patients had a single fracture (83%), 
while 17% of all patients had two or more. By fracture site, vertebral fracture 
accounted for 76.3% of all fractures, followed by 9.9% for hip fracture and 7.5% 
for wrist fracture. The societal cost of OF increased annually, from $83.7 million 
in 2007 to $141.4 million in 2011. For the societal cost of OF, direct medical cost 
was $134.9 million in 2011, which includes cost of treatment ($88.3 million) and 
long-term care ($46.6 million). The direct non-medical cost (transportation and 
caregiver costs) was estimated at $6.5 million in 2011. Costs associated with 
morbidity and mortality of OF were excluded due to the characteristics of the 
patients such as age, disability level and age at death. CONCLUSIONS: The 
results of this study indicate that the economic burden associated with OF in 
elderly people in Korea is considerable and is expected to rise with the predicted 
increases in life expectancy and the number of elderly in South Korea. Therefore, 
effective management of the disease is necessary to reduce the growth in the 
economic burden of OF.  
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OBJECTIVES: To describe drug use, drug switch and cost evaluation in patients 
with rheumatoid arthritis (RA). METHODS: Data derived from ARNO Observatory, 
an Italian population-based patient-centric system through record linkage of 11 
million inhabitants. In a sub-cohort of 5,821,337 people, we identified 15,082 
subjects with rheumatoid arthritis in 2011. Data were retrived for all these 
patients back to 2010 in order to esteem disease incidence. A cohort matched by 
sex, age and local health unit was computed to estimate differences in health 
costs. RESULTS: Prevalence of RA was 0.26% with an average age of 62 years and 
a percentage of women of 77%. Incidence is about 0.03% per year. The cost per-
person is €2,823 per year, 128% more in comparison with pair-matched group. 
This cost is for €1,230 due to drugs (€564 specific drugs, €666 others), €1,024 due 
to hospitalization and €569 due to lab tests and diagnostic examinations. Most 
common drugs are methylprednisolone+prednisone (63% treated), methotrexate 
(47.2%) and hydroxychloroquine (31.6%). Biological drugs are used by 3% of 
patients, but this percentage is increasing by years. Patients treated with 
biological drugs cost three times higher than others. Patients usually start first 
treatment with methylprednisolone+prednisone (46.6%), 25.2% start with 
methylprednisolone+prednisone and other specific drugs and 12.1% with 
methotrexate. One year after the first treatment only 40.1% of patients continue 
receiving the same treatment, 41.4% add a specific drug, 11.7% leave therapy and 
6.8% switch to another specific drug. CONCLUSIONS: This administrative 
database is an important source of information that is able to show both 
economical indicators and the good practice of treatment. In this study, they 
point out an elevated cost per-person in drugs assumption and show very 
current tendency to switch therapy in the first year.  
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OBJECTIVES: To identify factors associated with the cost of RA care and calculate 
risk-adjusted costs associated with RA in Turkey. We also examined the 
relationships between costs of RA treatment and global disease activity. 
METHODS: This cross-sectional study was performed in 10 university 
rheumatology centers. Eligible patients were ≥18 years of age and diagnosed with 
RA for at least 12 months according to the American College of Rheumatology 
(ACR) 1987 criteria. Generalized linear models were used to calculate risk-
adjusted direct costs. After using the Park test, the Gamma family with log link 
was chosen for the model. Age, gender, region, RA-related medication use and 
comorbidities such as diabetes, cardiovascular and respiratory disease, allergy 
and surgery were controlled in the model. Costs were adjusted by exchange rate 
of €1=2.30 Turkish Lira. RESULTS: A total of 698 patients (82% female; mean age: 
51.2±13.17 standard deviation [SD] years) were studied. Patients’ visual analog 
scale (VAS), patient’s global disease activity (GDA) and routine assessment of 
patient index data 3 (RAPID-3) scores were on average 44.15, 5.19 and 5.10 
respectively. Most patients were prescribed immunosuppressive medication and 
glucocorticoids (87.8% and 61.2%, respectively). Risk adjusted costs were 
estimated as €2,671. The most significant portion of overall expenditures was 
due to pharmaceutical costs €1987, while outpatient costs were €303, inpatient 
costs were €360 and co-payments were €21. 14% of patients experienced work 
loss due to RA. On average, annual costs due to workday loss were €480. 5.4% of 
patients also had other RA-related consultations, which were not covered by 
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insurance, bringing the average annual burden to €1600 for these patients. 
CONCLUSIONS: The annual medical cost of RA is significantly lower in Turkey 
relative to European estimates. With higher expenditures, there is a potential for 
a decrease in disease activity.  
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ANKYLOSING SPONDYLITIS HEALTH CARE COSTS AND ASSOCIATED DISEASE 
ACTIVITY SCORES IN TURKEY  
Akkoç N1, Direskeneli H2, Erdem H3, Gul A4, Kabasakal Y5, Kiraz S6, Durguner B7, Baser O8, 
Hamuryudan V9 
1Dokuz Eylül University, Izmir, Turkey, 2Marmara University Faculty of Medicine, Istanbul, 
Turkey, 3Gulhane Military Medical Academy, Ankara, Turkey, 4Istanbul University Faculty of 
Medicine, Istanbul, Turkey, 5Ege University, Izmir, Turkey, 6Hacettepe University, Ankara, 
Turkey, 7Pfizer Pharmaceuticals, Istanbul, Turkey, 8STATinMED Research/The University of 
Michigan, Ann Arbor, MI, USA, 9Istanbul University Cerrahpasa Faculty of Medicine, Istanbul, 
Turkey  
OBJECTIVES: To explore the direct health care resources associated with 
ankylosing spondylitis (AS) in Turkey, and establish how treatment intensity, 
proxied by AS treatment expenditures, affects disease activity. METHODS: 
Medical records of 650 prevalent AS patients attending seven centers at tertiary 
health care institutions nationwide were examined to assess the annual direct 
health care costs. Eligible patients were age ≥18 and diagnosed with AS for at 
least 12 months. To identify direct costs, overall costs were categorized as 
inpatient, outpatient, pharmacy and copay. Generalized linear models were used 
to determine factors affecting annual health care costs. Costs were adjusted by 
exchange rate of €1=2.30 Turkish Lira. RESULTS: The average patient age was 
40.1±11.33 standard deviation (SD) years and 35% of AS patients were female. 
Average disease duration was 7.9 years and more than 25% of patients suffered 
from at least one comorbidity. 7.54% of AS patients received inpatient care, 
92.77% received outpatient care and 95.23% weAre prescribed at least one 
medication. 66.77% of patients were prescribed disease-modifying anti-
rheumatic drugs (DMARDs). The mean (median) annual cost per patient was 
€6,059 (€6,825). The most significant portion of overall expenditures was due to 
drug cost (€5,728), while outpatient costs totaled €254 and inpatient costs €68. 
Copayments were relatively low at €12.3. Age and gender had no effect on 
annual health care costs. 54.92% of AS patients experienced work loss due to 
their condition. On average, annual cost due to work loss was calculated at €412. 
Two percent of patients also had other AS-related consultations, which were not 
covered by insurance. The average annual burden for these patients was €2482. 
CONCLUSIONS: Inpatient and outpatient costs for AS patients are lower in 
Turkey relative to other European countries. Treatment intensity inversely 
affects GDA, indicating that GDA can be improved by increasing treatment 
intensity.  
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OBJECTIVES: The introduction of biologic therapies has dramatically changed  
the management of psoriatic arthritis (PsA). The study aimed to estimate long-
term costs of biologics in the treatment of psoriatic arthritic patients in the 
United States. METHODS: We developed a 10-year Markov model describing the 
treatment pathway of patients with psoriatic arthritis who had failed prior  
oral DMARD therapy, using monthly cycles. Clinical efficacy data were obtained 
from published pivotal study results and literature. Costs, resource utilisation 
and treatment pathways were obtained from literature and expert opinion. 
Patients transitioned through two lines of biologics (etanercept, infliximab, 
golimumab or adalimumab as first or second line) followed by best supportive 
care. Response to therapy was defined as the probability of PsARC response at 
the end of the trial period. Patients transitioned to the next line of therapy in 
case of non-response or discontinuation due to other causes (a short-term 
annual drop-out rate of 32% and a long-term rate of 16.5% were assumed). All-
cause death was included and adjusted to reflect the increased mortality 
associated with PsA. Treatment and administration, monitoring, and 
hospitalisation costs were included. An annual discount rate of 3% was used. 
Probabilistic sensitivity analysis was conducted on key model parameters. For 
each first-line biologic option, average results across second-line biologic 
therapies were reported. RESULTS: From a third-party payer’s perspective, the 
estimated 10-year cumulative direct costs per patient were $214,642 (95% Crl: 
$214,171; $221,074) with etanercept as first-line biologic therapy, $203,140 (95% 
CrI: $202,632; $208,398) with infliximab, $218,703 (95% Crl: $217,992; $224,255) 
with golimumab and $208,840 (95% CrI: $208,192; $215,014) with adalimumab. 
Across scenarios, drug costs represented between 89.4% and 91.1% of total costs, 
monitoring costs between 4.5% and 6.3%, and hospitalisation costs between 4.3% 
and 4.9%. CONCLUSIONS: Biologic therapies represent a significant cost burden 
to payers.  
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OBJECTIVES: To determine health care costs of patients with rheumatoid 
arthritis (RA) from a single health plan who switch first- and second-line biologic 
disease-modifying antirheumatic drug (bDMARD) therapy. METHODS: This 
observational, retrospective analysis utilized administrative claims from a large, 
commercial health plan database containing insured beneficiaries between 
January 1, 2006 and December 31, 2010. The first-line population consisted of 
patients with RA, newly initiated on abatacept, etanercept, infliximab or 
adalimumab, with 12 months of continuous follow-up. A new second-line 
patient cohort was defined as those initiating a bDMARD with evidence of a 
different bDMARD up to 2 years prior to index date. Switching was defined as a 
different bDMARD claim within a 200% gap in days supply from the previous 
bDMARD claim. The days supply for bDMARDs was imputed based on the 
product label. Among switchers, the post-index period was divided into post-
initiation pre-switch and post-switch periods. All post-index costs were monthly 
and calculated only for the time the patient was on a bDMARD. Bivariate and 
multivariate statistical analyses were conducted to determine costs of bDMARD 
switchers versus non-switchers. RESULTS: Patients who switched first-line 
bDMARD therapy had higher baseline monthly health care costs than non-
switchers ($2417 vs. $2081; p<0.001). Post-index, first-line switchers had 
significantly higher costs after switch than non-switchers ($6081 vs. $4415), as 
did second-line switchers ($8376 v.s $5625). After controlling for potential 
confounders, post-switching costs were increased by 35% (least squares [LS] 
mean $5693 vs. $4224; p<0.001) for first-line switchers and by 46% (LS mean 
$7799 vs. $5348; p<0.001) for second-line switchers, versus non-switchers. 
CONCLUSIONS: Compared with non-switchers, health care costs are 
significantly higher for both first- and second-line switchers following switch. 
These findings reinforce the importance of understanding the implications 
associated with switching bDMARD therapy.  
 
PMS28  
THE PHARMACOECONOMIC AND HEALTH RELATED QUALITY OF LIFE  
IN RHEUMATOID ARTHRITIS (RA) PATIENTS IN A TERTIARY CARE  
HOSPITAL  
Nagappa AN1, Khera K2, Rau NR3 
1Manipal University, Manipal, India, 2Manipal College of Pharmaceutical Sciences, Manipal, 
Karnataka, India, 3Manipal Univiersity, Manipal, India  
OBJECTIVES: To determine the average cost of treatment incurred, to perform 
pharmacoeconomic analysis of drug therapy and to study changes in patient 
economic burden with disease activity for RA patients. METHODS: The study 
design was observational. Patient’s bill and insurance status was collected from 
the finance department for 250 RA patients. Inclusion and exclusion criteria were 
followed as per the ACR Guidelines (1987 and 2010). Patient drug therapy and 
disease activity were recorded from individual CRF& hospital records. RESULTS: 
Of 250RA patients female to male ratio was found to be 3:1. 67% of patients 
admitted were ages b/w 40–60years. The average days of hospitalization was 
found to be 7 days with average bed charges of INR 649 per patient. The total cost 
of therapy incurred per patient was INR 8961. The highest contribution was 
made by medications (INR 1920/patient), biochemical investigation charges 
(INR1561), doctor fees (INR1006), X-ray charges (INR385), physiotherapy 
procedures (INR320).These charges were found to vary within the patient 
population group based on the stage of the disease &presence/absence of co–
morbid conditions. CONCLUSIONS: Medication costs along with investigation 
charges are the highest contributors to the total expenses incurred by RA 
patients &has direct impact on HRQOL. These costs seem to vary from patient to 
patient based on Disease Activity Score and also presence of co–morbid 
conditions. Hence it becomes vital to diagnose and control the disease at an 
early stage to control the economic burden on the patient.  
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OBJECTIVES: To describe the best supportive care costs of psoriatic arthritis 
patients following discontinuation of DMARD therapy. METHODS: Adult patients 
with ≥2 PsA diagnoses (from office visits) with continuous insurance coverage ≥ 
6-month before (baseline period) and ≥12-month post-index date were selected 
from the MarketScan Commercial and Medicare Claims database (2005-2009). 
The index date was defined as the last day of DMARD coverage. Discontinuation 
was defined as no DMARD treatment for ≥12 consecutive months from the last 
day of DMARD prescription coverage. Patients were classified as having 
discontinued from a biologic if there was evidence of biologic DMARD use during 
the baseline period; otherwise they were defined as having discontinued from 
non-biologic DMARD. Twelve-month average costs following discontinuation 
were reported. RESULTS: A total of 1656 PsA patients met the selection criteria; 
63.2% were discontinued on non-biologic DMARD therapy and 36.8% on biologic 
therapy. Of non-biologic DMARD users, 59.7% were on methotrexate and 40.3% 
on other DMARDS. Over the 12-month period following discontinuation, total 
costs were $14,359 (SD: 23,375) and $10,144 (SD: 17,312) for biologic and non-
biologic users, respectively (p < 0.001). Outpatient and hospital/ER costs were 
significantly higher for the biologic discontinuers compared to the non-biologic 
discontinuers ($7,606 vs. $5,429, p=0.002, and $3,439 vs. $2,066, p<0.013, 
respectively) and accounted for 77% and 74% of total costs, respectively. 
Similarly, biologic users had higher drug costs ($3,314 vs. $2,649, p <0.002, 
respectively). CONCLUSIONS: This study suggests that outpatient and 
hospital/ER costs account for a substantial proportion of health care costs in PsA 
patients who discontinued from DMARD therapy. Patients who had discontinued 
from biologic DMARD therapy incurred higher outpatient, hospital and drug 
costs compared to patients who had discontinued from non-biologic DMARD 
therapy.  
